Patents by Inventor Brian Harms
Brian Harms has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170335015Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: ApplicationFiled: June 9, 2017Publication date: November 23, 2017Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
-
Publication number: 20170306415Abstract: The present invention provides methods for selecting a therapy for, or for providing a treatment to, a patient having a cancer. The methods of the present invention comprise detecting the protein biomarkers c-Met, HGF, and EpCAM in cancer cells or cancerous tissues of a subject, and predicting the subject's responsiveness to treatment with a c-Met-targeted or other HGF-inhibitory treatment, thereby enabling the selection and administration of an effective therapeutic.Type: ApplicationFiled: October 1, 2015Publication date: October 26, 2017Applicant: Merrimack Phamaceuticals, Inc.Inventors: Adnan ABU-YOUSIF, Aaron FULGHAM, Brian HARMS, Gavin MACBEATH, Victoria RIMKUNAS
-
Publication number: 20170307631Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: ApplicationFiled: December 20, 2016Publication date: October 26, 2017Inventors: Birgit SCHOEBERL, Brian HARMS, Francis David GIBBONS, Jonathan Basil FITZGERALD, Matthew David ONSUM, Ulrik NIELSEN, William KUBASEK
-
Publication number: 20170218028Abstract: Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.Type: ApplicationFiled: December 9, 2016Publication date: August 3, 2017Inventors: Brian HARMS, Neeraj KOHLI, Alexey LUGOVSKOY, Stephen SU, Melissa GEDDIE
-
Patent number: 9718892Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: GrantFiled: December 14, 2015Date of Patent: August 1, 2017Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
-
Publication number: 20170081421Abstract: Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs bind to the cell surface receptors c-Met and EpCam and inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.Type: ApplicationFiled: September 30, 2016Publication date: March 23, 2017Inventors: Brian HARMS, Neeraj KOHLI, Alexey Alexandrovich LUGOVSKOY, Melissa GEDDIE, Eric Mark KRAULAND, William George ROACH, Stephen SU, Adnan ABU-YOUSIF
-
Publication number: 20170054569Abstract: In one embodiment, one or more systems may receive input from a user identifying an interactive region of a physical environment. The one or more systems may determine a location of the interactive region relative to a depth sensor and monitor, at least in part by the depth sensor, the interactive region for a predetermined event. The one or more systems may detect, at least in part by the depth sensor, the predetermined event. In response to detecting the predetermined event, the one or more systems may initiate a predetermined action associated with the predetermined event.Type: ApplicationFiled: February 3, 2016Publication date: February 23, 2017Inventors: Brian Harms, Pol Pla, Yedan Qian, Olivier Bau
-
Patent number: 9458245Abstract: Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs bind to the cell surface receptors c-Met and EpCam and inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.Type: GrantFiled: March 6, 2014Date of Patent: October 4, 2016Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Brian Harms, Neeraj Kohli, Alexey Lugovskoy, Melissa Geddie, Eric Mark Krauland, William George Roach, Stephen Su, Adnan Abu-Yousif
-
Publication number: 20160168269Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: ApplicationFiled: December 14, 2015Publication date: June 16, 2016Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
-
Publication number: 20160086379Abstract: In one embodiment, a method includes presenting to a user, on a display of a head-worn client computing device, a three-dimensional video including images of a real-life scene that is remote from the user's physical environment. The method also includes presenting to the user, on the display of the head-worn client computing device, a graphical object including an image of the user's physical environment or a virtual graphical object.Type: ApplicationFiled: September 16, 2015Publication date: March 24, 2016Inventors: Sajid Sadi, Sergio Perdices-Gonzalez, Rahul Budhiraja, Brian Dongwoo Lee, Ayesha Mudassir Khwaja, Pranav Mistry, Link Huang, Cathy Kim, Michael Noh, Ranhee Chung, Sangwoo Han, Jason Yeh, Junyeon Cho, Soichan Nget, Brian Harms, Yedan Qian, Ruokan He
-
Patent number: 9238080Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: GrantFiled: May 20, 2011Date of Patent: January 19, 2016Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
-
Publication number: 20140302035Abstract: Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs bind to the cell surface receptors c-Met and EpCam and inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.Type: ApplicationFiled: March 6, 2014Publication date: October 9, 2014Applicants: ADIMAB, LLC, MERRIMACK PHARMACEUTICALS, INC.Inventors: Brian HARMS, Neeraj KOHLI, Alexey LUGOVSKOY, Melissa GEDDIE, Eric Mark KRAULAND, WIlliam George ROACH, Stephen SU, Adnan ABU-YOUSIF
-
Publication number: 20140294834Abstract: Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.Type: ApplicationFiled: February 20, 2014Publication date: October 2, 2014Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Brian HARMS, Neeraj KOHLI, Alexey LUGOVSKOY, Stephen SU, Melissa GEDDIE
-
Publication number: 20140178380Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: ApplicationFiled: February 24, 2014Publication date: June 26, 2014Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham Groton, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Publication number: 20140127238Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: ApplicationFiled: January 6, 2014Publication date: May 8, 2014Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit SCHOEBERL, Brian HARMS, Francis David GIBBONS, Jonathan Basil FITZGERALD, Matthew David ONSUM, Ulrik NIELSEN, William KUBASEK
-
Patent number: 8691771Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: GrantFiled: May 20, 2011Date of Patent: April 8, 2014Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
-
Patent number: 8623592Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted124 based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: GrantFiled: August 17, 2009Date of Patent: January 7, 2014Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Birgit Schoeberl, Brian Harms, Francis David Gibbons, Jonathan Basil Fitzgerald, Matthew David Onsum, Ulrik Nielsen, William Kubasek
-
Publication number: 20110293579Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.Type: ApplicationFiled: May 20, 2011Publication date: December 1, 2011Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun Lippow
-
Publication number: 20110286976Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.Type: ApplicationFiled: May 20, 2011Publication date: November 24, 2011Applicant: MERRIMACK PHARMACEUTICALSInventors: ULRIK NIELSEN, THOMAS WICKHAM, BIRGIT SCHOEBERL, BRIAN HARMS, BRYAN LINGGI, MATTHEW ONSUM, BYRON DELABARRE
-
Publication number: 20110159513Abstract: The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided.Type: ApplicationFiled: August 17, 2009Publication date: June 30, 2011Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Birgit Schoeberl, Brian Harms, Francis David Gibbons, Jonathan Basil Fitzgerald, Matthew David Onsum, Ulrik Nielsen, William Kubasek